Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. Peripheral nerve sheath tumors and NF1-related tumors (closed to accrual 09 / 19 / 2018) 29. The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer. Study will last 3 months, 20 … US - Breast Cancer Clinical Trials Overview 5.1 By Drug Class 5.2 By Formulation 5.3 By Organization 5.4 By Patient Segment 5.5 By Phase 5.6 By Target 6. Some breast cancer trials have temporarily stopped enrolling new patients. Swain S et al. Trastuzumab is a form of “targeted therapy” because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. Location: 26 locations, This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced urothelial carcinoma (UC) (including bladder, renal pelvis, ureter, urethra), renal cell carcinoma (RCC), castration-resistant prostate cancer (CRPC), non-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), endometrial cancer (EC), hepatocellular cancer (HCC), gastric cancer / gastroesophageal junction cancer / lower esophageal cancer (GC / GEJC / LEC), colorectal cancer (CRC), head and neck (H&N) cancer, and differentiated thyroid cancer (DTC). Location: 911 locations, This phase III trial compares the effect of cisplatin or carboplatin (platinum based chemotherapy) to capecitabine after surgery for the treatment of residual triple-negative breast cancer. Due to the nature of this study design, some tumor cohorts may complete enrollment earlier than others. Rare pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma. Sentinel lymph node resection compared with conventional axillary lymph node dissection in clinically node negative patients with breast cancer: overall survival findings from the NSABP B-32 randomized phase 3 trial. Fisher B, et al. (closed to accrual) 23. PD-L1 amplified tumors 50. 2017;389:1195–205. Clear cell cervical cancer 43. The study consists of two stages: in the Dose Escalation Stage, an appropriate recommended cabozantinib dose for the combination with standard dosing regimen of atezolizumab will be established; in the Expansion Stage, tumor-specific cohorts will be enrolled in order to further evaluate the safety and efficacy of the combination treatment in these tumor indications. In systemic management, an early trial by Bonadonna et al. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. These trials relate to the multidisciplinary management of breast cancer from the perspective of a radiation oncologist. One exploratory single-agent atezolizumab (SAA) cohort may also be enrolled with CRPC subjects. The clinical trials on this list are for breast cancer. Cell tumor of the testes and extragonadal germ tumors: A) Seminoma and testicular sex cord cancer B) Non-seminomatous tumor C) Teratoma with malignant transformation (closed to accrual) 17. Location: 1372 locations, This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. Location: 1083 locations, This randomized phase III trial studies lymph node dissection and radiation therapy to see how well it works compared to radiation therapy alone in treating patients with breast cancer previously treated with chemotherapy and surgery. J Clin Oncol. It is not known whether giving olaparib with or without atezolizumab will work better in patients with non-HER2-positive breast cancer. Location: 28 locations, This is an open-label, multicenter, multinational, Phase 2 basket study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in participants with HER (EGFR, HER2) mutation-positive solid tumors. The PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) trial was a 2 x 2 factorial, randomized controlled trial of candesartan and metoprolol in women with early breast cancer … This chapter contains a summary of some key findings from a selection of 24 trials related to breast cancer. At the moment they recommend that women at high or moderate risk of breast cance… 2005;97(22):1652–62. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body’s immune system. NSABP trials were among the first to demonstrate that the oral hormonal therapy, tamoxifen, could reduce the risk of breast cancer recurrence and improve survival. Gestational trophoblastic disease (GTD) 47. The dietary modification trial studied the effect of a diet low in fat and high in fruits, vegetables, and grains on the prevention of breast and colorectal cancer and heart disease. 2013;31(19):2382–7. Location: 575 locations, This randomized phase III trial studies how well paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body (metastatic). Location: 544 locations, This randomized phase III trial studies if not giving regional radiotherapy is just as good as using regional radiotherapy in keeping breast cancer from coming back in patients with estrogen receptor (ER) positive, HER2 negative node positive low risk breast cancer who have undergone breast conserving surgery or mastectomy. 2010;28:5132–9. N Engl J Med. that evaluated a MammaPrint risk stratification system are included as representative of how molecular and genetic innovations promise to transform cancer management. Basal cell carcinoma (temporarily closed to accrual 04 / 29 / 2020) 42. The research team found that laser treatment may be a good treatment option for early stage breast cancer in the future. Many women will also receive radiotherapy to the whole breast / chest area and the surrounding lymph glands (called regional radiotherapy). N Engl J Med. Participants with ER+/HER2- breast cancer … Trophoblastic tumor: A) Choriocarcinoma (closed to accrual) 15. Perez E, et al. Angiosarcoma 51. Location: 15 locations, This randomized phase II trial studies the side effects of capecitabine and how well it works when it is given dose-dense, fixed-dose as compared to standard dose in treating patients with breast cancer or gastrointestinal cancer that has spread from where it started to other places in the body or gastrointestinal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment. Fibromixoma and low grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary (closed to accrual 03 / 20 / 2018) 8. Location: 1034 locations, This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Cite as. Ask whether the combination of drugs proposed for your chemotherapy have been through clinical trials Patients will get T-DM1 injections from the study site staff on the first day of every cycle. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Research has looked at whether drugs could prevent breast cancer in women with an increased risk of the disease. Clear cell ovarian cancer (closed to accrual) 46. Effect of Radiotherapy After Mastectomy and Axillary Surgery on 10-year Recurrence and 20-year Breast Cancer Mortality: Meta-analysis of Individual Patient Data from 8135 Women in 22 Randomized Trials. This randomized phase III compares weight loss interventions in treating overweight and obese women with a higher risk for breast cancer that comes back (recurrence). The 2020 conference went online and saw a number of clinically significant results presented that will help inform the treatment of breast cancer in the clinic and guide further clinical trials. While doctors are still unclear on what causes breast cancer, research has allowed them to get a … TAILORx is one of the first trials to examine a methodology for personalizing cancer treatment. At the moment they recommend that women at high or moderate risk of breast cance… Pheochromocytoma, malignant (closed to accrual) 25. Trials measured cancer severity in terms of clinical stage (0 to IV), 23, 24, 68, 69 number of involved lymph nodes (0, 1 to 3, or ≥4), 18, 20, 25, 26, 70 and tumor size (mm), 19, 21, 26 and these varied across trials. Subjects enrolled in the SAC cohorts and SAA cohort may receive combination treatment with both cabozantinib and atezolizumab after they experience radiographic progressive disease per the Investigator per RECIST 1.1. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. NSABP B-06: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. Malignant giant cell tumors 30. Location: 33 locations, This randomized pilot phase II trial studies how well fulvestrant with or without palbociclib and avelumab works in treating patients with hormone receptor positive, HER2 negative breast cancer that has spread to other parts of the body or that has come back after a period of improvement and cannot be removed by surgery, and have been previously treated with CDK and endocrine therapy. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. At present, upon completion of chemotherapy and surgery, the standard of care for patients with triple-negative breast cancer is observation. BRCA-P is an international breast cancer prevention clinical trial which will enrol 2918 patients. Sarcomatoid carcinoma of lung 12. The National Institute for Health and Clinical Excellence (NICE) provide guidance for women at higher risk of breast cancer. Background: Breast cancer patients have a lifelong 2-4-fold increased risk of developing a second primary tumor in the contralateral breast compared with the risk for a first primary breast cancer in the general female population. This material is provided for educational purposes only and with the goal of encouraging further study about the landmark trials that have impacted oncology. Every year researchers from more than 90 countries come together for the San Antonio Breast Cancer Symposium. All trials on the list are supported by NCI. Patients will swallow tucatinib pills or placebo pills two times every day. Gastrointestinal stromal tumor (GIST) (closed to accrual 09 / 26 / 2018) 38. Patients in this study will be randomly assigned to get either tucatinib or placebo (a pill with no medicine). Adenocarcinoma with variants of small intestine (closed to accrual 05 / 10 / 2018) 6. J Clin Oncol. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Location: 23 locations, This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1 / 2 / 3, ROS1, or ALK gene fusion. Lancet. Dale Shepard, MD, PhD: So in terms of reaching out specifically to patients within breast cancer trials and breast cancer care, how big of a role does social media, patient support groups, how big of a role does that play in terms of patient awareness of a trial … J Natl Cancer Inst. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer. It is not yet known whether radiation therapy with or without olaparib may work better in treating patients with inflammatory breast cancer. Monoclonal antibodies, such as pertuzumab, may interfere with the ability of cancer cells to grow and spread. 1995;332(14):901–6. Neuroendocrine carcinoma including carcinoid of the lung (closed to accrual 12 / 19 / 2017) 24. ... Summary. Three studies are included that lessened the burden of surgery including the NSABP B-04, NSABP B-06, and NSABP B-32 trials. The study has randomized more than 10,200 women with this type of breast cancer at 1,182 sites in the … The clinical trials on this list are for breast cancer. This trial; Search. Fisher B, et al. J Clin Oncol. A 15-year meta-analysis conducted by the Early Breast Cancer Trialists’ Collaborative Group of long-term outcomes among 100,000 women treated in 123 randomized trials to evaluate polychemotherapy demonstrated a 10-year breast cancer … Randomized data on chemoprevention • Prospective, double-blind, randomized trial • Involved 19,747 postmenopausal females and studied tamoxifen versus raloxifene in preventing breast cancer • The final analysis initiated after at least 327 incident invasive breast cancers were diagnosed: 163 and 168 cases of invasive breast cancer in tamoxifen and raloxifene treated groups • No differences were found for other invasive cancer … The vaccine was developed by researchers at the Cleveland Clinic in Ohio and works by training the … Paraganglioma (closed to accrual 11 / 29 / 2018) 26. This may also predict for increased benefit with immunotherapy. We searched PubMed and oncology congress websites (American Society of Clinical Oncology, San Antonio Breast Cancer Symposium, European Society of Medical Oncology) between Jan 1, 2000, and Sept 1, 2015, to identify clinical trials of CDK4/6 inhibitors in combination with adjuvant endocrine therapy for patients with oestrogen-receptor-positive, HER2-negative early breast cancer… Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. This trial was open for people to join between 2012 and 2015, and the team published the results in 2018. For endocrine management, the NSABP B-14, NSABP B-20, NSABP B-24, NSABP P-01, and a meta-analysis by the Early Breast Cancer Trialists’ Collaborative Group are included. Monoclonal antibodies, such as avelumab, may help the immune system in detecting and fighting tumor cells. Endocrine therapy with fulvestrant prevents growth of hormone receptor positive breast cancer by blocking stimulation of tumor cells by estrogen.